Antibiotic Resistance Market Size, Trends & Growth Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Antibiotic Resistance Market Size Analysis

Global Antibiotic Resistance Market Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.S.
1. By Disease
  1. Introduction
    1. Disease By Value
  2. cUTI (Complicated Urinary Tract Infections)
    1. By Value
  3. CDI (Clostridioides difficile Infection)
    1. By Value
  4. ABSSSI (Acute bacterial skin and skin structure infections)
    1. By Value
  5. HABP (Hospital-acquired bacterial pneumonia)
    1. By Value
  6. CABP (Community-acquired pneumonia)
    1. By Value
  7. cIAI (Complicated intra-abdominal infection)
    1. By Value
  8. BSI (Bloodstream infection)
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. coli
    1. By Value
  3. pneumoniae
    1. By Value
  4. aeruginosa
    1. By Value
  5. aureus
    1. By Value
  6. baumannii
    1. By Value
  7. influenzae
    1. By Value
  8. difficile
    1. By Value
  9. faecium
    1. By Value
3. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Oxazolidinones
    1. By Value
  3. Lipoglycopeptides
    1. By Value
  4. Tetracyclines
    1. By Value
  5. Combination therapies
    1. By Value
  6. Cephalosporins
    1. By Value
  7. Others
    1. By Value
4. By Mechanism of Action
  1. Introduction
    1. Mechanism of Action By Value
  2. Protein Synthesis Inhibitors
    1. By Value
  3. Cell Wall Synthesis Inhibitors
    1. By Value
  4. RNA Synthesis Inhibitors
    1. By Value
  5. DNA Synthesis Inhibitors
    1. By Value
  6. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.K.
1. By Disease
  1. Introduction
    1. Disease By Value
  2. cUTI (Complicated Urinary Tract Infections)
    1. By Value
  3. CDI (Clostridioides difficile Infection)
    1. By Value
  4. ABSSSI (Acute bacterial skin and skin structure infections)
    1. By Value
  5. HABP (Hospital-acquired bacterial pneumonia)
    1. By Value
  6. CABP (Community-acquired pneumonia)
    1. By Value
  7. cIAI (Complicated intra-abdominal infection)
    1. By Value
  8. BSI (Bloodstream infection)
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. coli
    1. By Value
  3. pneumoniae
    1. By Value
  4. aeruginosa
    1. By Value
  5. aureus
    1. By Value
  6. baumannii
    1. By Value
  7. influenzae
    1. By Value
  8. difficile
    1. By Value
  9. faecium
    1. By Value
3. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Oxazolidinones
    1. By Value
  3. Lipoglycopeptides
    1. By Value
  4. Tetracyclines
    1. By Value
  5. Combination therapies
    1. By Value
  6. Cephalosporins
    1. By Value
  7. Others
    1. By Value
4. By Mechanism of Action
  1. Introduction
    1. Mechanism of Action By Value
  2. Protein Synthesis Inhibitors
    1. By Value
  3. Cell Wall Synthesis Inhibitors
    1. By Value
  4. RNA Synthesis Inhibitors
    1. By Value
  5. DNA Synthesis Inhibitors
    1. By Value
  6. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
China
1. By Disease
  1. Introduction
    1. Disease By Value
  2. cUTI (Complicated Urinary Tract Infections)
    1. By Value
  3. CDI (Clostridioides difficile Infection)
    1. By Value
  4. ABSSSI (Acute bacterial skin and skin structure infections)
    1. By Value
  5. HABP (Hospital-acquired bacterial pneumonia)
    1. By Value
  6. CABP (Community-acquired pneumonia)
    1. By Value
  7. cIAI (Complicated intra-abdominal infection)
    1. By Value
  8. BSI (Bloodstream infection)
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. coli
    1. By Value
  3. pneumoniae
    1. By Value
  4. aeruginosa
    1. By Value
  5. aureus
    1. By Value
  6. baumannii
    1. By Value
  7. influenzae
    1. By Value
  8. difficile
    1. By Value
  9. faecium
    1. By Value
3. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Oxazolidinones
    1. By Value
  3. Lipoglycopeptides
    1. By Value
  4. Tetracyclines
    1. By Value
  5. Combination therapies
    1. By Value
  6. Cephalosporins
    1. By Value
  7. Others
    1. By Value
4. By Mechanism of Action
  1. Introduction
    1. Mechanism of Action By Value
  2. Protein Synthesis Inhibitors
    1. By Value
  3. Cell Wall Synthesis Inhibitors
    1. By Value
  4. RNA Synthesis Inhibitors
    1. By Value
  5. DNA Synthesis Inhibitors
    1. By Value
  6. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
UAE
1. By Disease
  1. Introduction
    1. Disease By Value
  2. cUTI (Complicated Urinary Tract Infections)
    1. By Value
  3. CDI (Clostridioides difficile Infection)
    1. By Value
  4. ABSSSI (Acute bacterial skin and skin structure infections)
    1. By Value
  5. HABP (Hospital-acquired bacterial pneumonia)
    1. By Value
  6. CABP (Community-acquired pneumonia)
    1. By Value
  7. cIAI (Complicated intra-abdominal infection)
    1. By Value
  8. BSI (Bloodstream infection)
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. coli
    1. By Value
  3. pneumoniae
    1. By Value
  4. aeruginosa
    1. By Value
  5. aureus
    1. By Value
  6. baumannii
    1. By Value
  7. influenzae
    1. By Value
  8. difficile
    1. By Value
  9. faecium
    1. By Value
3. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Oxazolidinones
    1. By Value
  3. Lipoglycopeptides
    1. By Value
  4. Tetracyclines
    1. By Value
  5. Combination therapies
    1. By Value
  6. Cephalosporins
    1. By Value
  7. Others
    1. By Value
4. By Mechanism of Action
  1. Introduction
    1. Mechanism of Action By Value
  2. Protein Synthesis Inhibitors
    1. By Value
  3. Cell Wall Synthesis Inhibitors
    1. By Value
  4. RNA Synthesis Inhibitors
    1. By Value
  5. DNA Synthesis Inhibitors
    1. By Value
  6. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Disease
1. Introduction
  1. Disease By Value
2. cUTI (Complicated Urinary Tract Infections)
  1. By Value
3. CDI (Clostridioides difficile Infection)
  1. By Value
4. ABSSSI (Acute bacterial skin and skin structure infections)
  1. By Value
5. HABP (Hospital-acquired bacterial pneumonia)
  1. By Value
6. CABP (Community-acquired pneumonia)
  1. By Value
7. cIAI (Complicated intra-abdominal infection)
  1. By Value
8. BSI (Bloodstream infection)
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. coli
  1. By Value
3. pneumoniae
  1. By Value
4. aeruginosa
  1. By Value
5. aureus
  1. By Value
6. baumannii
  1. By Value
7. influenzae
  1. By Value
8. difficile
  1. By Value
9. faecium
  1. By Value
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Oxazolidinones
  1. By Value
3. Lipoglycopeptides
  1. By Value
4. Tetracyclines
  1. By Value
5. Combination therapies
  1. By Value
6. Cephalosporins
  1. By Value
7. Others
  1. By Value
By Mechanism of Action
1. Introduction
  1. Mechanism of Action By Value
2. Protein Synthesis Inhibitors
  1. By Value
3. Cell Wall Synthesis Inhibitors
  1. By Value
4. RNA Synthesis Inhibitors
  1. By Value
5. DNA Synthesis Inhibitors
  1. By Value
6. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
Brazil
1. By Disease
  1. Introduction
    1. Disease By Value
  2. cUTI (Complicated Urinary Tract Infections)
    1. By Value
  3. CDI (Clostridioides difficile Infection)
    1. By Value
  4. ABSSSI (Acute bacterial skin and skin structure infections)
    1. By Value
  5. HABP (Hospital-acquired bacterial pneumonia)
    1. By Value
  6. CABP (Community-acquired pneumonia)
    1. By Value
  7. cIAI (Complicated intra-abdominal infection)
    1. By Value
  8. BSI (Bloodstream infection)
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. coli
    1. By Value
  3. pneumoniae
    1. By Value
  4. aeruginosa
    1. By Value
  5. aureus
    1. By Value
  6. baumannii
    1. By Value
  7. influenzae
    1. By Value
  8. difficile
    1. By Value
  9. faecium
    1. By Value
3. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Oxazolidinones
    1. By Value
  3. Lipoglycopeptides
    1. By Value
  4. Tetracyclines
    1. By Value
  5. Combination therapies
    1. By Value
  6. Cephalosporins
    1. By Value
  7. Others
    1. By Value
4. By Mechanism of Action
  1. Introduction
    1. Mechanism of Action By Value
  2. Protein Synthesis Inhibitors
    1. By Value
  3. Cell Wall Synthesis Inhibitors
    1. By Value
  4. RNA Synthesis Inhibitors
    1. By Value
  5. DNA Synthesis Inhibitors
    1. By Value
  6. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Antibiotic Resistance Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Sanofi
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Pfizer Inc.
Merck & Co., Inc.
GSK plc.
Abbott
Johnson & Johnson
Novartis AG
Bayer AG
Shionogi & Co., Ltd.
Acurx Pharmaceuticals, Inc.
Melinta Therapeutics LLC
Paratek Pharmaceuticals, Inc.
VenatoRx Pharmaceuticals, Inc.
Spero Therapeutics
Summit Therapeutics Inc.
Theravance Biopharma.
Wockhardt
Zai Lab
Xellia Pharmaceuticals
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment